1. Homepage
  2. Equities
  3. China
  4. Shenzhen Stock Exchange
  5. Shijiazhuang Yiling Pharmaceutical Co., Ltd.
  6. News
  7. Summary
    002603   CNE1000015S0

SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

(002603)
  Report
End-of-day quote Shenzhen Stock Exchange  -  05-18
23.10 CNY   -1.91%
05/02Yiling Pharmaceutical's Q1 Profit Tumbles 28% as Sales Plummet
MT
04/29Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2021
CI
04/28Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Shunten International Limited Enters into Cooperation Framework Agreement with Shijiazhuang Yiling Pharmaceutical Co., Limited

12/30/2021 | 08:08am EDT

The board of directors of Shunten International (Holdings) Limited announced that the Company entered into a cooperation framework agreement with Shijiazhuang Yiling Pharmaceutical Co., Limited on 30 December 2021 (after trading hours) in relation to the potential business cooperation between the Company and Shijiazhuang Yiling Pharmaceutical (the "Potential Business Cooperation") subject to the terms and conditions of the definitive and legally-binding agreement(s) (the "Formal Agreement(s)"). The Cooperation Framework Agreement shall be valid for two years from the date of the Cooperation Framework Agreement. Pursuant to the Cooperation Framework Agreement, the Company and Shijiazhuang Yiling Pharmaceutical have principally agreed to cooperate on the following aspects: Shijiazhuang Yiling Pharmaceutical will introduce the Group's products to Mainland China for distribution through cross-border e-commerce platform; Shijiazhuang Yiling Pharmaceutical will assist the Company to submit domestic product registration in Mainland China. Upon obtaining the registration approval, Shijiazhuang Yiling Pharmaceutical will become the agent of selling the Group's products in Mainland China; The Company will make use of the current 100,000 domestic pharmacies directly accessible to Shijiazhuang Yiling Pharmaceutical and the 300,000 pharmacies within the reach of intermediates, to conduct off-line sales in the 400,000 pharmacies combined; The Company will assist Shijiazhuang Yiling Pharmaceutical to submit product registration of certain products in Hong Kong. Upon obtaining the registration approval, the Company will have priority to obtain exclusive distribution rights of the relevant products in Hong Kong; Product sales and brand cooperation in Hong Kong: the Company will assist Shijiazhuang Yiling Pharmaceutical to register and sell the products of Shijiazhuang Yiling Pharmaceutical based on the current strategic cooperative distribution facilitator stores of the Group in Hong Kong, including an aggregate of approximately 550 physical stores and approximately 50 sales counters with in-store salespersons; The Company and Shijiazhuang Yiling Pharmaceutical will collaborate to set up medical service centers in Hong Kong through integration of the medical resources in Mainland China, including utilization of existing personnel and doctors of Shijiazhuang Yiling Pharmaceutical via telemedicine in order to promote the high-quality Chinese medical services in Hong Kong. The potential Chinese medical services to be provided to Hong Kong citizens includes cross-border telemedicine services, onsite medical consultation and diagnosis services, Chinese medicine prescription and dispensing services.


© S&P Capital IQ 2021
All news about SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
05/02Yiling Pharmaceutical's Q1 Profit Tumbles 28% as Sales Plummet
MT
04/29Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year ..
CI
04/28Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Qua..
CI
04/18Yiling Pharma's Shares Sink on Doubts Over COVID-19 Drug Efficacy
MT
2021Shunten International Limited Enters into Cooperation Framework Agreement with Shijiazh..
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced a financing transaction
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year..
CI
2021HS Bio Sdn. Bhd. Enters into MOU with Shijiazhuang Yiling Pharmaceutical Co., Ltd
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces 2020 Final Distribution Plan to ..
CI
2021Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Dividend for the Year 2020
CI
More news
Financials
Sales 2022 12 094 M 1 802 M 1 802 M
Net income 2022 1 642 M 245 M 245 M
Net Debt 2022 - - -
P/E ratio 2022 23,6x
Yield 2022 -
Capitalization 38 660 M 5 760 M 5 760 M
Capi. / Sales 2022 3,20x
Capi. / Sales 2023 2,71x
Nbr of Employees 15 155
Free-Float 40,9%
Chart SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Duration : Period :
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 23,10 CNY
Average target price 31,49 CNY
Spread / Average Target 36,3%
EPS Revisions
Managers and Directors
Xiang Jun Wu Director & General Manager-Marketing Center
Chen Guang Li Chief Financial Officer & Director
Yi Ling Wu Chairman
Xue Dong Gao Chairman-Supervisory Board
Zhen Wang Independent Director